Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) EBITDA Margin (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBITDA Margin for 5 consecutive years, with 4834.11% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin fell 99707.0% to 4834.11% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 9107.4% through Dec 2025, down 220409.0% year-over-year, with the annual reading at 1591.77% for FY2023, N/A changed from the prior year.
  • EBITDA Margin hit 4834.11% in Q2 2025 for Kezar Life Sciences, down from 5080.4% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 8869.81% in Q4 2021 to a low of 364.67% in Q3 2023.
  • Historically, EBITDA Margin has averaged 5601.58% across 5 years, with a median of 5964.43% in 2022.
  • Biggest five-year swings in EBITDA Margin: soared 95578bps in 2023 and later plummeted -112571bps in 2024.
  • Year by year, EBITDA Margin stood at 8869.81% in 2021, then plummeted by -32bps to 6001.1% in 2022, then plummeted by -106bps to 364.67% in 2023, then soared by 1699bps to 5831.17% in 2024, then decreased by -17bps to 4834.11% in 2025.
  • Business Quant data shows EBITDA Margin for KZR at 4834.11% in Q2 2025, 5080.4% in Q1 2025, and 5831.17% in Q2 2024.